key: cord-1017701-nfasu94m
authors: Le Guen, Claire L.; King, Neil A.; Zhao, Huaqing; Renza-Stingone, Elizabeth P.; Gerhard, Glenn S.; Soans, Rohit S.
title: COVID-19 Patients with Obesity at Risk for Worse Outcomes Despite Younger Age and Fewer Inflammatory Derangements
date: 2021-06-24
journal: Surg Obes Relat Dis
DOI: 10.1016/j.soard.2021.06.006
sha: 0887ec12a16c2f5e681df749742e99c36c6760a9
doc_id: 1017701
cord_uid: nfasu94m

BACKGROUND: COVID-19 is a viral pulmonary infection which can progress to cytokine storm syndrome as a result of widespread dysregulated inflammatory response. Many patients at risk for severe COVID-19 manifestation have been identified as those with pre-existing conditions of pulmonary origin, as well as conditions which impair appropriate immune response, such as obesity. OBJECTIVES: The aim of this study is to describe the manifestation, clinical course, and inflammatory biomarker milieu of COVID-19 in patients with obesity. SETTING: Philadelphia, Pennsylvania. METHODS: In this retrospective cohort study, 600 COVID-19 positive patients were stratified by World Health Organization (WHO) obesity class and their presenting symptoms, disease biomarkers, demographics, and outcomes [intubation rate, intensive care unit (ICU) admission, length of stay (LOS), mortality)] were investigated. RESULTS: Age was inversely related to obesity class; patients of obesity class III presented 12.9 years younger than patients of normal weight (p<0.0001). Initial ferritin lab values were negatively correlated with increasing obesity class (p=0.0192). Normal or near-normal lymphocyte profile was noted in patients with obesity compared to patients without obesity (p=0.0017). Patients with obesity had an increased rate of ICU admission (p=0.0215), increased length of stay (p=0.0004), but no differences in intubation rate (p=0.3705) or mortality (p=0.2486). CONCLUSIONS: Patients with obesity were more likely to present to the hospital at a younger age, with reduced levels of COVID-19 related biomarker disturbances, increased LOS and ICU admission rates, though were not at increased risk for mortality.

classified as a global pandemic on March 12 th 2020. At the time of writing, the number of cases has skyrocketed, with the World Health Organization reporting over 21 million cases and more 40 than 761,000 deaths globally. As of September 2020, the United States bears the greatest burden of the disease with over 5.2 million cases and more than 167,000 deaths [1] .

The presentation of COVID-19 can vary widely among patients. While a significant number of patients infected with SARS-CoV-2 are asymptomatic or minimally symptomatic with cold-like 3 presence of lymphopenia, are indicators of severe COVID-19 disease [3] . D-dimer, a fibrin 50 degradation product signaling prothrombotic states, has also been shown to correlate with disease severity [4] . Measuring these biomarkers in patients with COVID-19 has become more common in clinical practice with the aim of identifying those at greatest risk for severe disease.

The manifestation of COVID-19 in patients with obesity has been of particular interest in the 55 United States, where the prevalence of obesitydefined as body mass index (BMI) >30 kg/m 2is 42.4%, and the prevalence of class III obesity (BMI >40 kg/m 2 ) is reported at 9.2% [5] .

Multiple early reports have described increasing trends of younger patients with obesity requiring hospitalization, and in some cases, increased risk of mortality [6, 7] . However, little has been described in terms of the clinical course of these patients as they present for 60 hospitalization for COVID-19. This is an important area of investigation, as patients with obesity are a prevalent subgroup of the United States population. People with obesity represent a demographic that is younger in age, as well as one with more disease burden compared to agematched peers without obesity [8] . In the United States, the obesity rates are highest among people aged 20-39 (40.0%), and people aged 40-59 (44.8%) [5] . People with obesity also often 65 have baseline underlying respiratory deficits, such as asthma, obesity hypoventilation syndrome, obstructive sleep apnea (OSA), and pulmonary hypertension, in addition to the diseases which constitute metabolic syndrome, such as diabetes mellitus, hypertension, and hyperlipidemia [9, 10] . Patients with obesity also exhibit basal levels of chronic inflammation, altered immune response, increased inflammatory response, and abnormal T-cell response, which further 70 increases their risk profile [11] . With a respiratory disease such as COVID-19, which has been shown to negatively affect people with underlying lung problems, as well as those with J o u r n a l P r e -p r o o f 4 hypertension and diabetes, it is important to characterize how this disease presents and manifests in people with obesity, who are often affected by several of these high-risk co-morbidities.

The objective of this study was to characterize the clinical presentation of COVID-19 in patients with obesity, investigate their outcomes, and describe their early presenting symptoms and inflammatory biomarker trends during their clinical course. 

Continuous data was expressed with means (SD) or medians (IQR had a history of substance abuse, and 6% had a history of malignancy. Detailed baseline demographic and co-morbidity characteristics are presented in Table 1 .

The most common presenting symptoms were fever (55.8%), cough (57.7%), and dyspnea (60.2%). Upon presentation to the emergency department, 31.7% required supplemental oxygen via nasal cannula, 10.0% required high flow nasal therapy (HFNT), 2.2% required non-invasive mechanical ventilation (NIMV), 3.0% required intubation and mechanical ventilation, and 53.2%

were maintained on room air. Detailed symptoms and signs data are presented in Table 2 .

Lymphopenia was common with 55.5% of patients presenting with an absolute lymphocyte count less than 1.0 K/mm 3 , and a median lymphocyte relative frequency of 16.2%. D-dimer was elevated in our cohort, with a median of 840.0 ng/mL. A negative correlation was identified 155 between ferritin and BMI ( Figure 2 ). Detailed laboratory findings are presented in Table 3 .

Absolute lymphocyte count and % lymphocyte were significantly positively correlated with BMI 

This study describes the demographic information, clinical presentation, and clinical laboratory features of 600 patients who were hospitalized for COVID-19 at a North Philadelphia academic medical center. The institution serves a predominately Black and Hispanic, medically underserved population, and is representative of many urban centers found throughout the United

States [12] . The aim of this study was to provide further insight into the disease presentation and 

In the zip codes directly served by this institution, obesity rates range from 32.3% to 39.5% [14] .

The rate of obesity in our hospitalized COVID-19 cohort was over 50%. increased oxygen consumption dedicated to respiratory work. This places them at risk for respiratory distress and subsequent failure with any pulmonary insult [9, 17, 18] . Patients with obesity are at high risk for pulmonary, cardiovascular, and metabolic co-morbidities [8, 19] .

Hypertension, diabetes mellitus, cardiovascular disease, and lung disease have been identified as independent risk factors for COVID-19 disease severity and mortality [15, 16, 20, 21] . Therefore, 215 obesity confers a higher risk of severe COVID-19 due to this constellation of altered respiratory physiology and high-risk co-morbidities.

We identified an inverse relationship between age and obesity class with regard to hospitalization rates. For every 5 kg/m 2 increase in BMI, the age of patients decreased 2.9 years. It is known that obesity is associated with chronic low-grade inflammation and immune dysregulation, resulting in baseline elevation of pro-inflammatory cytokines such as TNF-α, MCP-1, IL-6, and leptin [22] . TNF-α subsequently activates ferritin transcription, causing 230 J o u r n a l P r e -p r o o f 11 elevation of ferritin as an acute phase reactant, with chronic elevations in patients with obesity [23] . Ferritin levels can also be increased in obesity due to concomitant liver injury, i.e. nonalcoholic steatohepatitis, with damaged hepatic cells releasing ferritin to the systemic circulation [24] . It has been hypothesized that this chronic inflammatory state pre-disposes patients with obesity to severe disease manifestation as COVID-19 severity is largely driven by the 235 dysregulated inflammatory host response and subsequent damage. Our analysis identified a paradoxical association of lower ferritin levels on admission as BMI increased. Though the overall relationship between high ferritin levels and ICU admission was maintained, those with higher BMI who were admitted to the ICU had comparatively lower ferritin levels that those with a lower BMI who were admitted to the ICU.

In general, patients with obesity have also been recognized to be at higher risk for thrombotic events due to procoagulant imbalance and platelet hyperactivity [25] . Despite the demonstrated risk of thrombogenicity in obesity, the relationship between D-dimer and elevated BMI has yielded inconsistent results in literature. Variations in D-dimer levels have been proposed to be a 245 result of decreased fibrinolysis capacity in patients with obesity, yielding counteracting effects [26] . With COVID-19, a clearer relationship exists between elevated D-dimer levels and disease severity. Increased macro and micro-thrombotic events have been observed in patients with severe illness, and as such, D-dimer levels have been correlated with increasing severity of disease [29] . In our analysis, we did note a decreasing trend in admission D-dimer levels with 250 increasing BMI, however, after adjustment in multivariate analysis, this relationship was not statistically significant. The trend appeared to be largely driven by age, with increasing age and elevated D-dimer having an established relationship [30] . However, patients with severe illness J o u r n a l P r e -p r o o f 12 requiring ICU admission did demonstrate overall elevated admission D-dimer levels compared to those with milder disease who did not require ICU admission.

Lymphopenia in COVID-19 occurs early in the disease process and the degree of lymphopenia is prognostic for disease severity [31] . Patients in our obesity cohorts presented with normal, or near-normal lymphocyte relative frequency and absolute lymphocyte count compared to patients without obesity. Increased adiposity has been linked to an increased number of lymphocytes, 260 which may contribute to this finding [32] . This overall picture of decreased ferritin, and decreased lymphopenia in patients with increasing BMI portrays, at face value, a less severe presentation of COVID-19. However, there were significant differences in need for ICU admission and total in-hospital length of stay, though no differences in outcomes related to need for advanced respiratory support, or mortality were identified in our cohort.

Patients with obesity manifest significant respiratory symptoms necessitating hospitalization at a higher rate than their age matched peers. This may be because patients with obesity operate at a reduced respiratory functional state at baseline and the respiratory insult of an early or even mild SARS-CoV-2 infection manifestation is not well tolerated, resulting in respiratory distress and 270 hypoxemia. Additionally, it has been proposed that patients with obesity have a blunted proinflammatory response to viral infections, such as influenza, which may provide some insight into the reduced initial inflammatory response [22] . Despite having lower levels of biochemical and hematologic marker derangements upon admission, patients with obesity remain at elevated risk for ICU admission, and increased hospital length of stay. As inflammatory markers are 275 trended to direct therapy, understanding these mechanisms can be key to improving survival. 

Patients with obesity present with fewer derangements in admission inflammatory labs, specifically ferritin, absolute lymphocyte count, and lymphocyte %, however, tended to have increased hospital length of stay and increased need for ICU admission. As these markers are 305 frequently used to stratify patients by severity and guide treatment choice, it is important to recognize that these trends are manifest in patients with obesity and may subsequently have implications in their treatment course. A more complete understanding of the biochemical and inflammatory response to COVID-19 will be needed to improve outcomes in patients with obesity. Data are represented as no. (%) unless otherwise specified. p-values represent unadjusted comparison between obesity classes.

Abbreviations: BMI = body mass index, SD = standard deviation, COPD = chronic obstructive pulmonary disease J o u r n a l P r e -p r o o f 9.2 (9.6) 8.4 (6.7) 9.0 (7.8) 8.9 (10.0) 9.3 (8.5) 11.6 (14.9) 0.0004 Data are represented as no. (%), unless otherwise specified. p-values represent multivariable logistic regression, with adjustment for age, gender, and race, performed for secondary analysis. ______________________________________________________________ 12 data points greater than 5000 ng/mL were excluded (ranging from 5791-40,000) to enable visualization of data.

World Health Organization. Coronavirus disease (COVID-19) Situtation Report -209

Prevalence of asymptomatic SARS-CoV-2 infection : A narrative 325 review

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Dynamic relationship between D-dimer and COVID-19 severity

Prevalence of obesity and severe obesity among adults: United States

Morbid obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

The epidemiology of obesity: A big picture

The effect of obesity on lung function

Obesity hypoventilation syndrome epidemiology and diagnosis

COVID-19 and the role of chronic inflammation in patients with obesity

Public Health Management Corporation. Temple University Health System Community Health Needs Assessment

Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-355 19 in the Bronx

Public Health Management Corporation. Temple University Hospital

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

COVID-NET: COVID-19-associated hospitalization surveillance network n.d

Altered respiratory physiology in obesity

The impact of morbid obesity on oxygen cost of breathing (VO2RESP)) at rest

Health effects of overweight and obesity in 195 countries over 25 years

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Influenza and obesity: its odd relationship and the lessons for 380

COVID-19 pandemic

Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: Changes in transferrin uptake, iron handling and ferritin mRNA

Ferritin, metabolic syndrome and its components: A systematic review and metaanalysis

Inflammation, obesity, and thrombosis

Effects of Obesity Surgery on Blood Coagulation and Fibrinolysis: A Literature Review

ACE2 receptor expression 395 and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 400 (COVID-19): A systematic review and meta-analysis

COVID-19 and its implications for thrombosis and anticoagulation

Age-related adverse 405 inflammatory and metabolic changes begin early in adulthood

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

Lymphocytes and macrophages in adipose tissue in obesity: markers or makers of subclinical inflammation?

The independent risk of obesity and diabetes and their interaction in COVID-19: A 415 retrospective cohort study

We thank Dr. Gerard J. Criner for mentorship and assistance with data interpretation, Vikram J.Eddy for assistance with development of the figures, and the Temple University COVID-19Research Group for assistance with data acquisition and review.

This study received funding support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK R01DK120890).

The authors have no conflicts of interest to disclose. 

Data are represented as median (IQR), n if fewer patients were assessed for those laboratory studies than the total number of patients in the study. *p-values represent unadjusted comparison between obesity classes. †p-values represent multivariable linear regression with log transformation of inflammatory marker, with adjustment for age, gender, and race performed for secondary analysis. Abbreviations: BMI = body mass index, IQR = interquartile range